Literature DB >> 23306371

Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination.

Maria Paulke-Korinek1, Michael Kundi, Brigitte Laaber, Natascha Brodtraeger, Claudia Seidl-Friedrich, Ursula Wiedermann, Herwig Kollaritsch.   

Abstract

In a sample of originally 430 healthy adults (18-84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23306371     DOI: 10.1016/j.vaccine.2012.12.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013.

Authors:  Everardo Vega; Leslie Barclay; Nicole Gregoricus; S Hannah Shirley; David Lee; Jan Vinjé
Journal:  J Clin Microbiol       Date:  2013-10-30       Impact factor: 5.948

2.  Human CD4+ T Helper Cell Responses after Tick-Borne Encephalitis Vaccination and Infection.

Authors:  Judith H Aberle; Julia Schwaiger; Stephan W Aberle; Karin Stiasny; Ondrej Scheinost; Michael Kundi; Vaclav Chmelik; Franz X Heinz
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

3.  Tick-borne Encephalitis Vaccine Failures: A 10-year Retrospective Study Supporting the Rationale for Adding an Extra Priming Dose in Individuals Starting at Age 50 Years.

Authors:  Karin E Hansson; Anja Rosdahl; Mona Insulander; Sirkka Vene; Lars Lindquist; Sara Gredmark-Russ; Helena H Askling
Journal:  Clin Infect Dis       Date:  2020-01-02       Impact factor: 9.079

4.  Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture.

Authors:  Mikhail F Vorovitch; Karina G Grishina; Viktor P Volok; Liubov L Chernokhaeva; Konstantin V Grishin; Galina G Karganova; Aidar A Ishmukhametov
Journal:  Hum Vaccin Immunother       Date:  2020-05-19       Impact factor: 3.452

5.  A cross-sectional study evaluating tick-borne encephalitis vaccine uptake and timeliness among adults in Switzerland.

Authors:  Kyra D Zens; Vasiliki Baroutsou; Philipp Sinniger; Phung Lang
Journal:  PLoS One       Date:  2021-12-14       Impact factor: 3.240

6.  Retrospective, matched case-control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006-2020.

Authors:  Kyra D Zens; Sarah R Haile; Axel J Schmidt; Ekkehardt S Altpeter; Jan S Fehr; Phung Lang
Journal:  BMJ Open       Date:  2022-04-22       Impact factor: 3.006

7.  The Prevalence of Asymptomatic Infections with Tick-Borne Encephalitis Virus and Attitude towards Tick-Borne Encephalitis Vaccine in the Endemic Area of Northeastern Poland.

Authors:  Ewa Bojkiewicz; Kacper Toczylowski; Sambor Grygorczuk; Beata Zelazowska-Rutkowska; Justyna Dunaj; Agnieszka Zebrowska; Piotr Czupryna; Anna Moniuszko-Malinowska; Artur Sulik
Journal:  Vaccines (Basel)       Date:  2022-08-10

8.  Factors determining immunological response to vaccination against tick-borne encephalitis virus in older individuals.

Authors:  Pontus Lindblom; Peter Wilhelmsson; Linda Fryland; Andreas Matussek; Mats Haglund; Johanna Sjöwall; Sirkka Vene; Dag Nyman; Pia Forsberg; Per-Eric Lindgren
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

Review 9.  Primary vaccine failure to routine vaccines: Why and what to do?

Authors:  Ursula Wiedermann; Erika Garner-Spitzer; Angelika Wagner
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.